El Minister of Industry and Tourism, Jordi Hereu, today unveiled the new Profarma 2025-2026 Plan to representatives of the pharmaceutical sector. This program, designed to encourage greater investment in this strategic industry for Spain, seeks to strengthen one of the country's most innovative sectors, characterized by the use of advanced production technologies and high-quality research with highly qualified personnel.
Among the key incentives offered by the Profarma program is a Reduction in the contributions that pharmaceutical companies must make to the National Health SystemThese contributions are established in the Law on Guarantees and Rational Use of Medicines and Health Products, whereby companies that sell prescription drugs financed with public funds must contribute 1,5% or 2% of their sales.
The reduction of these contributions to the National Health System will depend directly on the classification that companies obtain within the Profarma programThe established categories are: acceptable (5%), good (10%), very good (15%) or excellent (25%). Additionally, companies will be able to benefit from a An additional 10% reduction for participation in R&D consortia or for forming temporary associations with other public and private companies and research centers in Spain, provided that these projects are focused on relevant basic and preclinical research.
The Profarma Plan 2025-2026 has as its primary goal Turn Spain into a European leader in both pharmaceutical production and drug development. In addition, it pursues Strengthen skilled employment, increase foreign investment, and promote public-private collaborationIn the current international context, promoting national drug manufacturing is crucial for reduce vulnerability to potential global crises and ensure security of supply in the country.
The new program will prioritize R&D&I activities, manufacturing and marketing of participating companies in areas such as strategic medicines, antimicrobials, biotechnological and advanced therapies, as well as those medicines with a lower environmental impact.
For the 2025-2026 edition, the Profarma program will assess aspects aligned with the Pharmaceutical Industry Strategy 2024-2028, the European Green Deal, the European Digital Strategy and the 2030 Agenda for Sustainable Development. It will also will boost the research activity of digital innovation centers, promoting the use of data and machine learning to drive innovation and the development of new medicines.
Throughout its more than three decades of existence, the Profarma program has been fundamental to strengthen the competitiveness of the Spanish pharmaceutical industry, attracting investment and generating quality employment. Participating companies consider the rating obtained a element of prestige that stimulates its performance in SpainIn the case of subsidiaries with multinational capital, this rating has become a key argument for attract new investments in the country.
Any questions about this news?
Talk to Coexia, the AI of the foreign trade
